Literature DB >> 3425649

Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulfate: a preliminary report.

G R Thurnau1, D B Kemp, A Jarvis.   

Abstract

The purpose of this study is twofold: (1) to correlate magnesium levels of serum with those of cerebrospinal fluid in patients with preeclampsia receiving intravenous magnesium sulfate, and (2) to determine whether the magnesium ion crosses the blood-brain barrier in significant amounts after intravenous magnesium sulfate therapy. Of the 21 patients in whom spinal anesthesia was used for delivery, ten patients with preeclampsia with therapeutic serum magnesium levels made up the study group and 11 term nontreated normotensive gravid women served as controls. At the time of spinal anesthesia, a 1 ml aliquot of cerebrospinal fluid was obtained from each patient. The mean cerebrospinal fluid magnesium level for the control group was 2.56 +/- 0.19 mg/dl (range 2.2 to 2.8 mg/dl). For the preeclamptic group who received intravenous magnesium sulfate, the mean cerebrospinal fluid magnesium level was 3.04 +/- 0.12 mg/dl (range 2.9 to 3.2 mg/dl). Although only a small amount of magnesium crosses the blood-brain barrier after intravenous magnesium sulfate treatment, this increment is highly significant (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3425649     DOI: 10.1016/s0002-9378(87)80239-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  16 in total

1.  The safety and feasibility of continuous intravenous magnesium sulfate for prevention of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  Abutaher M Yahia; Jawad F Kirmani; Adnan I Qureshi; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles.

Authors:  J F Lu; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

Review 4.  Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre-eclampsia.

Authors:  J Anthony; R B Johanson; L Duley
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 5.  Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness.

Authors:  K W Muir
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Magnesium sulfate and nimesulide have synergistic effects on rescuing brain damage after transient focal ischemia.

Authors:  Liang-Chao Wang; Chih-Yuan Huang; Hao-Kuang Wang; Ming-Hsiu Wu; Kuen-Jer Tsai
Journal:  J Neurotrauma       Date:  2012-03-29       Impact factor: 5.269

Review 7.  Use of magnesium in traumatic brain injury.

Authors:  Ananda P Sen; Anil Gulati
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 8.  Magnesium sulfate for the treatment of eclampsia: a brief review.

Authors:  Anna G Euser; Marilyn J Cipolla
Journal:  Stroke       Date:  2009-02-10       Impact factor: 7.914

9.  The Effect of Intravenous Magnesium Sulphate Treatment on the Spinal Anaesthesia Produced by Bupivacaine in Pre-eclamptic Patients.

Authors:  Mustafa Atçı; Hakkı Ünlügenç; Yasemin Güneş; Refik Burgut; Geylan Işık; Zehra Hatipoğlu; Mediha Türktan
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-09-09

10.  Magnesium Therapy in Pre-eclampsia Prolongs Analgesia Following Spinal Anaesthesia with Fentanyl and Bupivacaine: An Observational Study.

Authors:  Tülay Özkan Seyhan; Olgaç Bezen; Mukadder Orhan Sungur; Ibrahim Kalelioğlu; Meltem Karadeniz; Kemalettin Koltka
Journal:  Balkan Med J       Date:  2014-06-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.